Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy.

BACKGROUND Clinical trials of postmenopausal hormone therapy (HT) have shown increased risk of coronary heart disease (CHD) in the first few years after initiation of therapy and no overall benefit. METHODS This nested case-control study evaluates a range of inflammatory, lipid, thrombotic, and genetic markers for their association with CHD in the 4 years after randomization and assesses whether any of these markers modified or mediated the initially increased risk associated with HT in postmenopausal women aged 50 to 79 years at baseline. Conjugated equine estrogens, 0.625 mg/d, or placebo was given to 10 739 hysterectomized women, and the same estrogen plus medroxyprogesterone acetate, 2.5 mg/d, was given to 16 608 women with an intact uterus. RESULTS In multivariate-adjusted analyses of 359 cases and 820 controls in the combined trials, baseline levels of 12 of the 23 biomarkers studied were associated with CHD events: interleukin 6, matrix metalloproteinase 9, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, triglycerides, D-dimer, factor VIII, von Willebrand factor, leukocyte count, homocysteine, and fasting insulin. Biomarkers tended to be more strongly associated with CHD in the initial 2 years after randomization. The genetic polymorphism glycoprotein IIIa leu33pro was significantly associated with CHD. Baseline low-density lipoprotein cholesterol interacted significantly with HT so that women with higher levels were at higher risk for CHD when given HT (P = .03 for interaction). The levels of several biomarkers were changed by HT, but these changes did not seem to be associated with future CHD events. CONCLUSIONS Several thrombotic, inflammatory, and lipid biomarkers were associated with CHD events in postmenopausal women, but only low-density lipoprotein cholesterol modified the effect of HT. Further research is needed to identify the mechanisms by which HT increases the risk of CHD. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00000611.

[1]  R. Karas,et al.  Molecular and Cellular Basis of Cardiovascular Gender Differences , 2005, Science.

[2]  L. Shulman.  Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause , 2008 .

[3]  Jennifer G. Robinson,et al.  Lipoprotein Particle Concentrations May Explain the Absence of Coronary Protection in the Women's Health Initiative Hormone Trials , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[4]  P. Savage,et al.  The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[5]  L H Kuller,et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[6]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[7]  Constance K Haan,et al.  Evidence-based guidelines for cardiovascular disease prevention in women. , 2004, Circulation.

[8]  K. Korach,et al.  27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen , 2007, Nature Medicine.

[9]  Jennifer G. Robinson,et al.  Can Biomarkers Identify Women at Increased Stroke Risk? The Women's Health Initiative Hormone Trials , 2007, PLoS clinical trials.

[10]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[11]  Charles B Eaton,et al.  Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. , 2006, Archives of internal medicine.

[12]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[13]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[14]  P M Rautaharju,et al.  The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. , 1998, Journal of electrocardiology.

[15]  K. Yano,et al.  Plasma Fibrinogen as a Predictor of Total and Cause-Specific Mortality in Elderly Japanese-American Men , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[16]  J. Manson.  Estrogen plus progestin and risk of coronary heart disease , 2004 .

[17]  J. Weiss,et al.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. , 1996, The New England journal of medicine.

[18]  A. Sharrett,et al.  Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.